BR112022023049A2 - Proteínas multiespecíficas - Google Patents
Proteínas multiespecíficasInfo
- Publication number
- BR112022023049A2 BR112022023049A2 BR112022023049A BR112022023049A BR112022023049A2 BR 112022023049 A2 BR112022023049 A2 BR 112022023049A2 BR 112022023049 A BR112022023049 A BR 112022023049A BR 112022023049 A BR112022023049 A BR 112022023049A BR 112022023049 A2 BR112022023049 A2 BR 112022023049A2
- Authority
- BR
- Brazil
- Prior art keywords
- proteins
- nucleic acids
- multiespecific
- pharmaceutical compositions
- multispecific
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000008102 Ankyrins Human genes 0.000 abstract 1
- 108010049777 Ankyrins Proteins 0.000 abstract 1
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20174847 | 2020-05-14 | ||
| EP20181498 | 2020-06-22 | ||
| PCT/EP2021/062860 WO2021229067A1 (en) | 2020-05-14 | 2021-05-14 | Multispecific proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022023049A2 true BR112022023049A2 (pt) | 2022-12-20 |
Family
ID=75904957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022023049A BR112022023049A2 (pt) | 2020-05-14 | 2021-05-14 | Proteínas multiespecíficas |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20240279290A1 (https=) |
| EP (1) | EP4149959A1 (https=) |
| JP (1) | JP7843711B2 (https=) |
| KR (1) | KR20230022176A (https=) |
| CN (1) | CN115768786A (https=) |
| AU (1) | AU2021271129A1 (https=) |
| BR (1) | BR112022023049A2 (https=) |
| CA (1) | CA3178785A1 (https=) |
| CO (1) | CO2022017445A2 (https=) |
| IL (1) | IL298168A (https=) |
| MX (1) | MX2022014326A (https=) |
| TW (1) | TW202208408A (https=) |
| WO (1) | WO2021229067A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220113492A (ko) | 2019-12-11 | 2022-08-12 | 몰리큘라 파트너스 아게 | 변경된 표면 잔기를 갖는 설계된 안키린 반복 도메인 |
| IL298168A (en) | 2020-05-14 | 2023-01-01 | Molecular Partners Ag | Multispecific proteins |
| US11981710B2 (en) | 2020-08-18 | 2024-05-14 | Athebio Ag | N-terminal capping modules of ankyrin repeat domains |
| EP3957649A1 (en) | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| IL305677A (en) | 2021-03-09 | 2023-11-01 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
| IL313411A (en) * | 2021-12-14 | 2024-08-01 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| WO2025163082A1 (en) * | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| DE60140474D1 (de) | 2000-09-08 | 2009-12-24 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| BRPI0517834A (pt) | 2004-11-12 | 2008-10-21 | Bayer Schering Pharma Ag | vìrus da doença de newcastle recombinante |
| BRPI0613593A2 (pt) | 2005-07-08 | 2011-01-18 | Univ Zuerich | método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo |
| CA2700391A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zuerich | Designed armadillo repeat proteins |
| EP3785735A1 (en) | 2008-11-03 | 2021-03-03 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
| EP2483316A1 (en) | 2009-10-02 | 2012-08-08 | Ludwig Institute for Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| DK2643349T3 (da) | 2010-11-26 | 2019-11-25 | Molecular Partners Ag | Designede repeat-proteiner, der binder til serumalbumin |
| EP2702069A4 (en) | 2011-04-29 | 2015-04-29 | Janssen Biotech Inc | IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF |
| CA2877584A1 (en) | 2012-06-28 | 2014-01-03 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| CA2883264A1 (en) | 2012-10-15 | 2014-04-24 | Universitat Zurich Prorektorat Mnw | Bispecific her2 ligands for cancer therapy |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| US11453708B2 (en) | 2013-05-31 | 2022-09-27 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
| AU2016240220B2 (en) | 2015-04-02 | 2019-11-21 | Molecular Partners Ag | Designed ankyrin repeat domains with binding specificity for serum albumin |
| US10717772B2 (en) | 2016-09-22 | 2020-07-21 | Molecular Partners Ag | Recombinant binding proteins targeting HER2 and serum albumin, and their uses |
| AU2018247796A1 (en) * | 2017-04-04 | 2019-08-29 | F. Hoffmann-La Roche Ag | Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP |
| KR102782136B1 (ko) | 2017-11-08 | 2025-03-18 | 쿄와 기린 가부시키가이샤 | CD40과 EpCAM에 결합하는 이중특이적 항체 |
| NZ773887A (en) | 2018-10-01 | 2024-11-29 | Hoffmann La Roche | Bispecific antigen binding molecules comprising anti-fap clone 212 |
| US12441772B2 (en) | 2019-06-04 | 2025-10-14 | Molecular Partners Ag | Designed ankyrin repeat domain with improved stability |
| SG11202112925PA (en) | 2019-06-04 | 2021-12-30 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| EP3980452A1 (en) | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Recombinant 4-1bb binding proteins and their use |
| CN114206943A (zh) | 2019-06-04 | 2022-03-18 | 分子伴侣公司 | 多特异性蛋白质 |
| KR20220113492A (ko) | 2019-12-11 | 2022-08-12 | 몰리큘라 파트너스 아게 | 변경된 표면 잔기를 갖는 설계된 안키린 반복 도메인 |
| CA3161319A1 (en) | 2019-12-11 | 2021-06-17 | Victor LEVITSKY | Recombinant peptide-mhc complex binding proteins and their generation and use |
| KR20230006558A (ko) | 2020-05-06 | 2023-01-10 | 몰리큘라 파트너스 아게 | 신규한 안키린 반복 결합 단백질 및 그의 용도 |
| IL298168A (en) | 2020-05-14 | 2023-01-01 | Molecular Partners Ag | Multispecific proteins |
| US20240279309A1 (en) | 2020-05-14 | 2024-08-22 | Molecular Partners Ag | Recombinant cd40 binding proteins and their use |
| JP2023549316A (ja) | 2020-11-16 | 2023-11-24 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｆａｐを標的としたｃｄ４０アゴニストとの併用療法 |
| CA3202358A1 (en) | 2020-12-16 | 2022-06-23 | Andreas BOSSHART | Novel slow-release prodrugs |
| US20240052033A1 (en) | 2020-12-16 | 2024-02-15 | Molecular Partners Ag | Recombinant cd3 binding proteins and their use |
| TW202300644A (zh) | 2021-02-24 | 2023-01-01 | 中國大陸商杭州啟函生物科技有限公司 | 免疫細胞中的嵌合抗原受體 |
| AU2022233791A1 (en) | 2021-03-09 | 2023-09-28 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| JP2024509890A (ja) | 2021-03-09 | 2024-03-05 | モレキュラー パートナーズ アクチェンゲゼルシャフト | プロテアーゼ切断可能なプロドラッグ |
| WO2022190010A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd33 engagers |
| EP4319883A1 (en) | 2021-04-09 | 2024-02-14 | Molecular Partners AG | Novel darpin based cd70 engagers |
| IL313411A (en) | 2021-12-14 | 2024-08-01 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
-
2021
- 2021-05-14 IL IL298168A patent/IL298168A/en unknown
- 2021-05-14 TW TW110117538A patent/TW202208408A/zh unknown
- 2021-05-14 WO PCT/EP2021/062860 patent/WO2021229067A1/en not_active Ceased
- 2021-05-14 MX MX2022014326A patent/MX2022014326A/es unknown
- 2021-05-14 AU AU2021271129A patent/AU2021271129A1/en active Pending
- 2021-05-14 US US17/925,144 patent/US20240279290A1/en active Pending
- 2021-05-14 BR BR112022023049A patent/BR112022023049A2/pt unknown
- 2021-05-14 KR KR1020227043615A patent/KR20230022176A/ko active Pending
- 2021-05-14 CN CN202180044299.9A patent/CN115768786A/zh active Pending
- 2021-05-14 JP JP2022568689A patent/JP7843711B2/ja active Active
- 2021-05-14 CA CA3178785A patent/CA3178785A1/en active Pending
- 2021-05-14 EP EP21725187.5A patent/EP4149959A1/en active Pending
- 2021-05-14 US US17/302,898 patent/US12331090B2/en active Active
-
2022
- 2022-12-02 CO CONC2022/0017445A patent/CO2022017445A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023528204A (ja) | 2023-07-04 |
| TW202208408A (zh) | 2022-03-01 |
| JP7843711B2 (ja) | 2026-04-10 |
| MX2022014326A (es) | 2023-02-09 |
| AU2021271129A1 (en) | 2022-12-15 |
| CO2022017445A2 (es) | 2023-02-16 |
| KR20230022176A (ko) | 2023-02-14 |
| CN115768786A (zh) | 2023-03-07 |
| WO2021229067A1 (en) | 2021-11-18 |
| US20210395318A1 (en) | 2021-12-23 |
| AU2021271129A9 (en) | 2023-01-12 |
| US20240279290A1 (en) | 2024-08-22 |
| CA3178785A1 (en) | 2021-11-18 |
| EP4149959A1 (en) | 2023-03-22 |
| US12331090B2 (en) | 2025-06-17 |
| IL298168A (en) | 2023-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022023049A2 (pt) | Proteínas multiespecíficas | |
| BR112022011177A2 (pt) | Domínios de repetição de anquirina projetados com resíduos de superfície alterados | |
| BR112021024231A2 (pt) | Proteínas de ligação fap recombinantes e uso da mesma | |
| BR112022022456A2 (pt) | Proteínas de ligação de repetição de anquirina e seus usos | |
| BR112023020685A2 (pt) | Acopladores de cd70 baseados em darpin | |
| BR112021021224A2 (pt) | Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo | |
| MX2023007067A (es) | Proteinas recombinantes de union a cd3 y su uso. | |
| BR112017020986A2 (pt) | proteínas de ligação recombinantes e seu uso | |
| NZ754051A (en) | Novel antibodies and uses thereof | |
| BR112022002442A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| MX2019010958A (es) | Metodos de tratamiento de tumores. | |
| BR112018015238A2 (pt) | conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição | |
| BR112017026292A2 (pt) | muteína de lipocalina, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método de produção de muteína de lipocalina, métodos de ligação de lag-3 em pacientes, de estímulo da reação imunológica em pacientes, de indução da proliferação de linfócitos t, de interferir com a ligação de lag-3 humano e de detecção da presença de lag-3, composição farmacêutica, imunoconjugado, uso de muteína e kit analítico ou de diagnóstico | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| BR112015000776A2 (pt) | Agentes de ligação à rspo3 e usos dos mesmos | |
| BRPI0907637A8 (pt) | biomarcadores p53 | |
| BR112012020373A8 (pt) | anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico | |
| BR112023018293A2 (pt) | Acopladores de célula t multiespecíficos à base de darpin | |
| BR112021008774A2 (pt) | Formulação farmacêutica, agente de ligação, métodos para tratamento de uma doença, para produzir uma formulação farmacêutica, para induzir a morte celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, uso de uma formulação farmacêutica | |
| MX2021014649A (es) | Dominio de repetición de anquirina diseñado con estabilidad mejorada. | |
| BR112020024412A8 (pt) | Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação | |
| BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
| BR112021024997A2 (pt) | Anticorpos, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, métodos e uso | |
| BR112014029089A2 (pt) | anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2 | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico |